Pharma News, 2022

BioMarin Pharmaceutical will need to run additional preclinical studies to assess the "theoretical" cancer risk of a rare disease gene therapy it's developing, information the Food and Drug Adminis...

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today issued the following statement regarding the clinical trial of Hetero’s generic molnupiravir.  ...

The cough medicine dextromethorphan has been shown to treat inherited heart arrhythmia disorders in mouse models and human cells. 

FDA has approved Pyrukynd (mitapivat) tablets  to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with pyruvate kinase (PK) d...

The triazole moiety is present in a large number of FDA-approved drugs, drug candidates, and lead compounds. This heterocycle, for example, is considered as a privileged structure of antifungal com...

Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, similar to the non-communicable diseases cancer, obesity, cardiovascular disease and diabetes. ...

The first African countries selected to receive the technology necessary to produce mRNA vaccines against COVID-19 are Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia, a summit meeting of ...

A federal appeals court has upheld a decision ordering Teva Pharmaceuticals to pay $235.5 million to GlaxoSmithKline for infringing on the latter’s patent for its congestive heart failure drug Co...

The FDA has granted a Priority Review to Bristol Myers Squibb’s application for Breyanzi (lisocabtagene maraleucel) as a second-line treatment for adults with relapsed or refractory B-cell lymph...

The drug industry, patient advocates and congressional Republicans have all attacked federal officials' decision to decline routine Medicare coverage for a controversial Alzheimer's drug.  ...

Vaccine pioneers expand presence throughout Europe with a view to leveraging technology.

After dosing just one patient in a phase 1 trial, the FDA put a clinical hold on Legend Biotech’s early-stage CAR-T cell therapy, LB1901, which targets malignant CD4+ T-cells. ...